| Help us to promote this site! Link to us |
|
|
|
||||
| Email This Page to Friend | |||||
|
Breast Cancer News
|
||||
|
by AP 2 Sep 2010 at 3:01am Allergan Inc., the maker of wrinkle-smoothing Botox, has agreed to pay $600 million to settle a yearslong federal investigation into its marketing of the top-selling, botulin-based drug. by Reuters 2 Sep 2010 at 6:20am A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market. by HealthDay 2 Sep 2010 at 8:03am THURSDAY, Sept. 2 (HealthDay News) -- Many Americans have skewed perceptions when it comes to their weight, often believing they are lighter than they actually are, even when the scales are shouting otherwise, a new poll finds. by Reuters 2 Sep 2010 at 6:19am While staying mentally active in old age has been linked to a delayed onset of dementia, seniors who engage in such brain "exercise" may actually have a faster rate of decline once Alzheimer's is diagnosed, researchers reported Wedne... by AFP 2 Sep 2010 at 4:27am The chief of the UNAIDS agency said Thursday that global contributions to fighting the disease are dropping off for the first time in 15 years amid tough economic times. by Reuters 2 Sep 2010 at 11:21am Companies are cutting healthcare costs further amid a continuing sour economy, scaling back benefits and shifting a greater share of the expense to employees. by Reuters 2 Sep 2010 at 10:35am The estrogen-like compounds found in soy could help postmenopausal women get a better night's sleep, according to a small study. by Reuters 2 Sep 2010 at 12:19pm Women who start menstruating early may be at increased risk of asthma and poor lung function, new research shows. by Reuters 2 Sep 2010 at 2:33pm A cell phone text message -- and the buzz or beep that signals its arrival -- may not help a woman remember to pop her birth control pill, a new study suggests. by AFP 2 Sep 2010 at 1:05pm Researchers have discovered a promising new malaria drug with the potential to treat resistant strains of the deadly disease in a single dose, according to a study published Thursday in the journal Science. by Reuters 2 Sep 2010 at 2:38pm Pakistan's displaced flood victims say a lack of clean water and high temperatures are causing illnesses sweeping through relief camps with children most at risk. by Reuters 2 Sep 2010 at 1:54pm An experimental Novartis drug can clear malaria infection in mice with a single dose and scientists say it shows promise as a possible future treatment for one of the world's major killer diseases. by AFP 2 Sep 2010 at 2:16pm A groundbreaking new test can accurately diagnose drug-resistant tuberculosis (TB) in as little as two hours, researchers wrote in a study published Thursday in the New England Journal of Medicine. by Reuters 2 Sep 2010 at 1:46pm When it comes to changing health behaviors, it takes more than a far-flung network of friends on Facebook egging you on. It takes a jostling herd, U.S. researchers said on Thursday. by Reuters 2 Sep 2010 at 2:30pm A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market. |
12 Jan 2009 at 6:24am Higher-than-normal levels of insulin place postmenopausal women at increased risk of breast cancer, scientists at Albert Einstein College of Medicine of Yeshiva University report. Their findings, reported in the January 7 issue of the Journal of the National Cancer Institute, suggest that interventions that target insulin and its signaling pathways may decrease breast cancer risk in these women........12 Jan 2009 at 6:24am  The molecular details of Aromatase, the key enzyme mandatory for the body to make estrogen, are no longer a mystery thanks to the structural biology work done by the Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in Buffalo, New York. Dr. Debashis Ghosh's solution of the three-dimensional structure of aromatase is the first time that researchers have been able to visualize the mechanism of synthesizing estrogen........12 Jan 2009 at 6:24am  A team of scientists at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all patients with breast cancer, spreading the disease, resisting traditional chemotherapies and eventually leading to death. The gene, called "Metadherin" or MTDH, is located in a small region of human chromosome 8 and may be crucial to cancer's spread or metastasis because it helps tumor cells stick tightly to blood vessels in distant organs. The gene also makes tumors more resistant to the powerful chemotherapeutic agents normally used to wipe out the deadly cells........12 Jan 2009 at 6:24am  Women should go for the broccoli when the relish tray comes around during holiday celebrations this season. While it has been known for some time that eating cruciferous vegetables, such as broccoli, cauliflower, and cabbage, can help prevent breast cancer, the mechanism by which the active substances in these vegetables inhibit cell proliferation was unknown until now........12 Jan 2009 at 6:24am  Throughout the world, 10 million breast cancer survivors have a lifetime risk for developing lymphedema, a chronic condition that involves swelling of the limbs and impacts physical and psychosocial health. Second only to the recurrence of cancer, it is the most dreaded effect of breast cancer therapy. In a new study, University of Missouri scientists observed that the risk of developing lymphedema is 40 percent to 60 percent higher in women with body mass index (BMI) classified as overweight or obese in comparison to normal weight women. The scientists recommend increased health education for breast cancer survivors........12 Jan 2009 at 6:24am  A newly published genome sequence of a breast cancer cell line reveals a heavily rearranged genetic blueprint involving breaks and fusions of genes and a broken DNA repair machinery, said scientists at Baylor College of Medicine in a report that appears online in the journal Genome Research "It's like a computer program that has become buggy and transcends into something dangerous," said Dr. Aleksandar Milosavljevic, associate professor in the BCM Human Genome Sequencing Center. "It makes the cell escape normal controls on cell proliferation. Experimentally, some of the rearrangements in the genome that we found produce fusion genes that confer uncontrolled cell growth and prevent tumor cells from dying, allowing them to grow outside their normal tissue environment. These are all essential attributes of cancer"........12 Jan 2009 at 6:24am  Two separate meta-analyses of clinical trials from around the world that tested tamoxifen against aromatase inhibitor drugs in postmenopausal women with early breast cancer have each reached the same conclusion: aromatase inhibitors are more effective in preventing breast cancer from coming back. Patients using aromatase inhibitors had more than a 3 percent lower cancer recurrence 6-8 years after diagnosis, in comparison to women using tamoxifen alone........12 Jan 2009 at 6:24am  A lack of clear-cut, scientific evidence illustrating the benefits of mammography screening in women over 80 has created a trail of controversy leading to a disturbing conclusion about cancer care in America. "We are ill-prepared from a scientific knowledge perspective to provide cancer health care rationally, ethically, equitably and humanely to the 'booming' older population," say two leading cancer researchers........12 Jan 2009 at 6:24am  The University of Texas M. D. Anderson Cancer Center will hold the first international inflammatory breast cancer (IBC) conference on December 6-7, to bring together internationally recognized breast cancer clinicians and scientists. Participants will present new clinical discoveries and participate in educational workshops, with the goal of improving diagnosis and management of this rare but deadly disease........12 Jan 2009 at 6:24am  Diets that are high in protein and cereal grains produce an excess of acid in the body which may increase calcium excretion and weaken bones, as per a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology and Metabolism (JCEM). The study observed that increasing the alkali content of the diet, with a pill or through a diet rich in fruits and vegetables has the opposite effect and strengthens skeletal health........12 Jan 2009 at 6:24am  Tamoxifen may worsen breast cancer in a small subset of patients. Research published in BioMed Central's open access journal Breast Cancer Research suggests that in patients who show reduced or absent expression of the protein E-cadherin, usually used anti-oestrogen drugs such as tamoxifen may promote more harmful cancer cell behaviour........12 Jan 2009 at 6:24am  Breast-specific gamma imaging (BSGI) is effective in the detection of cancers not found on mammograms or by clinical exam, as per a research studypresented today at the annual meeting of the Radiological Society of North America (RSNA). "BSGI can identify the most difficult to detect breast cancerinvasive lobular carcinoma," said lead author Rachel F. Brem, M.D., professor of radiology and director of the Breast Imaging and Interventional Center at The George Washington University Medical Center in Washington, D.C. "It also can help us detect additional lesions of all types of breast cancer in women whose mammograms show only one suspicious lesion.".......12 Jan 2009 at 6:24am  A stunning discovery based on epigenetics (the inheritance of propensities acquired in the womb) reveals that consuming choline-a nutrient found in eggs and other foods-during pregnancy may significantly affect breast cancer outcomes for a mother's offspring. This finding by a team of biologists at Boston University is the first to link choline consumption during pregnancy to breast cancer. It also is the first to identify possible choline-related genetic changes that affect breast cancer survival rates........12 Jan 2009 at 6:24am  Breast cancer rates increased significantly in four Norwegian counties after women there began undergoing mammography every two years, as per a report in the November 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Rates among regularly screened women remained higher than rates among women of the same age who were screened only once after six years, suggesting that some of the cancers detected by mammography may have spontaneously regressed had they not been discovered and treated........12 Jan 2009 at 6:24am  Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss. But a new study has observed that cancer drugs aren't the only culprits. Among 64 patients with breast cancer referred to a bone health clinic, 78 percent had at least one other cause of bone loss, including vitamin D deficiency, excessive calcium excretion in urine and an overactive parathyroid gland........25 Sep 2007 at 10:41pm  The Human Papillomavirus (HPV) is considered the cause of one of the most important sexually transmitted diseases nowadays, and affects both men and women. HPV is so common in our society that only people who have never had sexual relations can be sure that they have not been exposed to this disease. However, as with other microbes, people infected do not necessarily develop the disease, because, in most cases, it only means the colonization. Only some of the people colonized will fall ill with different processes........25 Sep 2007 at 10:41pm  University of Florida scientists have identified a set of proteins that appear to signal the presence of bladder cancer, a discovery they hope will lead to a simple, fast and noninvasive test that can detect the disease early. Working with colleagues at the University of Michigan, the researchers used advances in technology to isolate nearly 200 proteins from the urine of patients with and without bladder cancer. Several appear promising as potential biomarkers, including one that studies conducted elsewhere have already associated with liver and ovary cancer. The findings, available online, are scheduled would be reported in the July 6 print edition of the American Chemical Societys Journal of Proteome Research........25 Sep 2007 at 10:41pm  Arsenic exposure appears to continue causing lung and bladder cancer deaths years after exposure ends, as per a research studypublished online June 12 in the Journal of the National Cancer Institute Arsenic is a known cause of lung and bladder cancer, but scientists dont yet know how long cancer risk remains elevated after arsenic exposure. The drinking water in a region of northern Chile became contaminated with very high amounts of arsenic beginning in 1958. In the 1970s, construction of water therapy plants in the region led to a decline in arsenic concentration. This sudden rise and fall of arsenic levels gave scientists the opportunity to investigate the period between first and last exposure to high levels of arsenic and subsequent mortality due arsenic-related cancers, such as bladder and lung cancer........25 Sep 2007 at 10:41pm  There are currently about fifty million smokers in the U.S. and there are another fifty million ex-smokers. Cigarette smoking has been linked to several human malignancies. Some of these links like the relationship between smoking and lung cancer are well established. In some other cases the relationship between smoking and cancer is not very well established. However several studies have clearly shown the malignant potential of chemical substances in cigarette smoke. This article is an attempt to summarize some of the known links between cigarette smoking and caner........25 Sep 2007 at 10:41pm As you are aware we are the leading publishers of health news on the web. We publish news items in various forms including numerous blogs and news items. We invite you to participate in our new collection. We are looking for quality news items that would be interesting to our readers. Now you may suggest the news item from your site to be included at Medicineworld.org. Inclusion of news item at our site get instantaneous attention since the item is illustrated from various blog posts. Addition of pictures to the item adds additional attraction to your news item. Inclusion in the Medicineworld.org site brings quality links and visitors to your site........ 25 Sep 2007 at 10:41pm Medicineworld wishes all our readers merry Christmas. Oh, jingle bells, jingle bells Jingle all the way...... 25 Sep 2007 at 10:41pm Emory Winship Cancer Institute is the only cancer research and treatment facility in Georgia to offer an innovative Phase II clinical trial for transitional cell carcinoma (TCC), a common form of bladder cancer. The clinical trial is testing the efficacy of the investigational drug Vinflunine. Vasily Assikis, MD, assistant professor of hematology and oncology and director of Winship's Prostate Cancer Translational Research Program is principal investigator....... 25 Sep 2007 at 10:41pm A new population-based study has found that patients 75 years of age or older with invasive bladder cancer are less likely to receive the recommended surgical treatment for the disease.The findings "suggest in a sense some undertreatment of our older patients," Dr. Brenda K. Edwards of the National Cancer Institute, Bethesda, Maryland, told Reuters Health. However, she noted, the study was unable to gauge the influence of factors such as patient choice, which also could have made surgery less common among older patients....... 25 Sep 2007 at 10:41pm Previous research from Ohio State and Harvard Universities showed that men who ate broccoli had half the risk of bladder cancer compared to those who did not. Now the researchers have isolated interesting compounds from broccoli sprouts. Known as glucosinolates, they are turned into isothiocyanates during chopping, chewing and digestion. Experiments with bladder cancer cells, including the most aggressive type, shows that the isothiocyanates can block their growth. The scientist believe there may be up to a dozen other compounds in broccoli that have a similar effect....... |
31 Aug 2010 at 10:47am Researchers say tens of thousands of women could avoid getting breast cancer each year if they got more gentle exercise in--particularly walking. 30 Aug 2010 at 3:40pm Scientists at Oxford University have discovered a link between vitamin D deficiency and genes related to both cancer and autoimmune diseases. 30 Aug 2010 at 3:11pm Drugs on the list include the birth control pill Inplanon, the breast cancer drug Herceptin, and the heart drug Multaq. 16 Aug 2010 at 9:54am A new study may reignite the debate on the risks posed by hormone replacement therapy (HRT) on breast cancer. 26 Jul 2010 at 12:14pm An advisory panel to the U.S. Food and Drug Administration has overwhelmingly voted to withdrawal approval for the breast cancer drug Avastin. 26 Jul 2010 at 12:05pm Women with African heritage are more prone to the deadlier "triple negative" type of breast cancer, researchers say. 12 Jul 2010 at 11:14am In the 1970s 44 percent of women diagnosed with breast cancer survived for at least 10 years, compared to 77 percent now. 12 Jul 2010 at 10:07am Seattle researchers followed over 35,000 post-menopausal women and found that those who regularly took a fish oil supplement had a 32 percent reduced risk of developing the most common form of breast cancer. 30 Jun 2010 at 2:55pm According to the Center for Science in the Public Interest (CSPI), food dyes commonly used in foods from cereals and candy to fruit drinks may cause hyperactivity, allergic reactions, and even cancer. 29 Jun 2010 at 11:45am Researchers say troublesome side effects keep many women from refilling their prescriptions for the recommended five-year period. 29 Jun 2010 at 11:43am Experts are urging cancer patients to exercise more in order to reduce fatigue and stave off physical changes that can last years. 25 Jun 2010 at 11:33am Women who take oral bisphosphonates for osteoporosis appear to have a reduced risk of some breast cancers, a new study has found. 21 Jun 2010 at 3:54pm Women who underwent psychological intervention during an initial bout of breast cancer handled the stress of recurrence and even had longer survival rates than their peers, a new study has found. 21 Jun 2010 at 3:43pm A blood test that can detect breast cancer up to a year in advance could dramatically improve survival rates, researchers say. 16 Jun 2010 at 6:36pm According to a new study, cancer survivors who do yoga sleep better, experience less fatigue, and have a slightly increased quality of life. |
by Aleix Prat 1 Sep 2010 at 7:00pm IntroductionIn breast cancer, gene expression analyses have defined five tumor subtypes (luminal A, luminal B, HER2-enriched, basal-like and claudin-low), each of which has unique biologic and prognostic features. Here, we comprehensively characterize the recently identified claudin-low tumor subtype. Methods: The clinical, pathological and biological features of claudin-low tumors were compared to the other tumor subtypes using an updated human tumor database and multiple independent data sets. These main features of claudin-low tumors were also evaluated in a panel of breast cancer cell lines and genetically engineered mouse models. Results: Claudin-low tumors are characterized by the low to absent expression of luminal differentiation markers, high enrichment for epithelial-to-mesenchymal transition markers, immune response genes and cancer stem cell-like features. Clinically, the majority of claudin-low tumors are poor prognosis estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and epidermal growth factor receptor 2 (HER2)-negative (triple negative) invasive ductal carcinomas with a high frequency of metaplastic and medullary differentiation. They also have a response rate to standard preoperative chemotherapy that is intermediate between that of basal-like and luminal tumors. Interestingly, we show that a group of highly utilized breast cancer cell lines, and several genetically engineered mouse models, express the claudin-low phenotype. Finally, we confirm that a prognostically relevant differentiation hierarchy exists across all breast cancers in which the claudin-low subtype most closely resembles the mammary epithelial stem cell. Conclusions: These results should help to improve our understanding of the biologic heterogeneity of breast cancer and provide tools for the further evaluation of the unique biology of claudin-low tumors and cell lines. by Yubo Chai 31 Aug 2010 at 7:00pm IntroductionNatural herbal compounds with novel actions different from existing breast cancer (BCa) treatment modalities are attractive for improving therapeutic efficacy and safety. We have recently shown that penta-1,2,3,4,6-O-galloyl-beta-D-glucose (PGG) induced S-phase arrest in prostate cancer (PCa) cells through inhibiting DNA replicative synthesis and G1 arrest, in addition to inducing cell death at higher levels of exposure. We and others have shown that PGG through intraperitoneal (i.p.) injection exerts a strong in vivo growth suppression of human PCa xenograft models in athymic nude mice. This study aims to test the hypothesis that the novel targeting actions of PGG are applicable to BCa cells, especially those lacking proven druggable targets. Methods: Mono-layer cell culture models of p53-wild type estrogen receptor (ER)-dependent MCF-7 BCa cells and p53-mutant ER-/progesterone receptor (PR)- and Her2-regular (triple-negative) MDA-MB-231 BCa were exposed to PGG for a comprehensive investigation of cellular consequences and molecular targets/mediators. To test the in vivo efficacy, female athymic mice inoculated with MDA-MB-231 xenograft were treated with 20mg PGG/kg body weight by daily gavage starting 4 days after cancer cell inoculation. Results: Exposure to PGG induced S-phase arrest in both cell lines as indicated by the lack of 5-bromo2'-deoxy-uridine (BrdU) incorporation into S-phase cells as well as G1 arrest. Higher levels of PGG induced more caspase-mediated apoptosis in MCF-7, in strong association with induction of P53 Ser15 phosphorylation, than in MDA-MB-231 cells. The cell cycle arrests were achieved without an induction of cyclin dependent kinase (CDK) inhibitory proteins P21Cip1 and P27Kip1. PGG treatment led to decreased cyclin D1 in both cell lines and over-expressing cyclin D1 attenuated G1 arrest and hastened S arrest. In serum-starvation synchronized MCF-7 cells, down-regulation of cyclin D1 was associated with de-phosphorylation of retinoblastoma (Rb) protein by PGG shortly before G1-S transition. In vivo, oral administration of PGG led to a greater than 60% inhibition of MDA-MB231 xenograft growth without adverse effect on host body weight. Conclusions: Our in vitro and in vivo data support PGG as a potential drug candidate for breast cancer with novel targeting actions, especially for a triple negative BCa xenograft model. by Fabio Parisi 31 Aug 2010 at 7:00pm IntroductionMulti-marker molecular assays have impacted management of early stage breast cancer, facilitating adjuvant chemotherapy decisions. We generated prognostic models that incorporate protein-based molecular markers and clinico-pathological variables to improve survival prediction. Methods: We used a quantitative immunofluorescence method to study protein expression of 14 markers included in the Oncotype DXTM assay on a 638 breast cancer patient cohort with 15-year follow-up. We performed cross-validation analyses to assess performance of multivariate Cox models consisting of these markers and standard clinico-pathological covariates, using an average time-dependent Area Under the Receiver Operating Characteristic curve and compared it to nested Cox models obtained by robust backward selection procedures. Results: A prognostic index derived from a multivariate Cox regression model incorporating molecular and clinico-pathological covariates (nodal status, tumor size, nuclear grade, and age) is superior to models based on molecular studies alone or clinico-pathological covariates alone. Performance of this composite model can be further improved using feature selection techniques to prune variables. When stratifying patients by Nottingham Prognostic Index (NPI), most prognostic markers in high and low NPI groups differed. Similarly, for the node-negative, hormone receptor-positive sub-population, we derived a compact model with three clinico-pathological variables and two protein markers that was superior to the full model. Conclusions: Prognostic models that include both molecular and clinico-pathological covariates can be more accurate than models based on either set of features alone. Furthermore, feature selection can decrease the number of molecular variables needed to predict outcome, potentially resulting in less expensive assays. by Christine Watson 30 Aug 2010 at 7:00pm Cancer vaccines are the holy grail for patients and clinicians alike. The possibility that we can be vaccinated against common cancers is very appealing and the socio-economic consequences significant. A recent paper from Vincent Tuohy's group, published in the journal Nature Medicine, suggests a new approach for the development of a prophylactic vaccine for breast cancer. Their strategy was to induce mammary gland failure in mice by immunization with an antibody specific to a milk protein that resulted in autoimmunity during lactation. This also showed some efficacy as a therapeutic vaccine. Can we look forward to the elimination of breast cancer? by Diana Cittelly 30 Aug 2010 at 7:00pm The vital role of ovarian hormones in the development of normal breast foreshadowed their importance in mammary stem cell regulation. Two recent papers reveal that 17-beta-estradiol and progesterone control the size and repopulating ability of the mammary stem cell compartment. This likely occurs via paracrine signaling from steroid receptor positive luminal cells to steroid receptor negative stem cells. These findings illuminate roles for the female sex steroids in mobilizing the stem cell pool in the normal breast, and also provide a crucial link between the known hormonal risks of breast cancer and the potential stem cell origin of this disease. by Vilde Haakensen 26 Aug 2010 at 7:00pm IntroductionMammographic density (MD), as assessed from film screen mammograms, is determined by the relative content of adipose, connective and epithelial tissue in the female breast. In epidemiological studies, a high percentage of MD confers a four to six fold risk elevation of developing breast cancer, even after adjustment for other known breast cancer risk factors. However, the biologic correlates of density are little known. Methods: Gene expression analysis using whole genome arrays was performed on breast biopsies from 143 women; 79 women with no malignancy (healthy women) and 64 newly diagnosed breast cancer patients, both included from mammographic centres. Percent MD was determined using a previously validated, computerized method on scanned mammograms. Significance analysis of microarrays (SAM) was performed to identify genes influencing MD and a linear regression model was used to assess the independent contribution from different variables to MD. Results: SAM-analysis identified 24 genes differentially expressed between samples from breasts with high and low MD. These genes included three uridine 5'-diphospho-glucuronosyltransferase (UGT) genes and the oestrogen receptor gene (ESR1). These genes were down-regulated in samples with high MD compared to those with low MD. The UGT gene products, which are known to inactivate oestrogen metabolites, were also down-regulated in tumour samples compared to samples from healthy individuals. Several single nucleotide polymorphisms (SNPs) in the UGT genes associated with the expression of UGT and other genes in their vicinity were identified. Conclusions: Three UGT enzymes were lower expressed both in breast tissue biopsies from healthy women with high MD and in biopsies from newly diagnosed breast cancers. The association was strongest amongst young women and women using hormonal therapy. UGT2B10 predicts MD independently of age, hormone therapy and parity. Our results indicate that down-regulation of UGT genes in women exposed to female sex hormones is associated with high MD and might increase the risk of breast cancer. by Jean Abraham 22 Aug 2010 at 7:00pm IntroductionTamoxifen is one of the most effective adjuvant breast cancer therapies available. Its metabolism involves the phase I enzyme, cytochrome P4502D6 (CYP2D6), encoded by the highly polymorphic CYP2D6 gene. CYP2D6 variants resulting in poor metabolism of tamoxifen are hypothesised to reduce its efficacy. An FDA-approved pre-treatment CYP2D6 gene testing assay is available. However, evidence from published studies evaluating CYP2D6 variants as predictive factors of tamoxifen efficacy and clinical outcome are conflicting, querying the clinical utility of CYP2D6 testing. We investigated the association of CYP2D6 variants with breast cancer specific survival (BCSS) in breast cancer patients receiving tamoxifen. Methods: This was a population based case-cohort study. We genotyped known functional variants (n=7; minor allele frequency (MAF)>0.01) and single nucleotide polymorphisms (SNPs) (n=5; MAF>0.05) tagging all known common variants (tagSNPs), in CYP2D6 in 6640 DNA samples from patients with invasive breast cancer from the SEARCH (Studies of Epidemiology and Risk factors in Cancer Heredity); 3155 cases had received tamoxifen therapy. There were 312 deaths from breast cancer, in the tamoxifen treated patients, with over 18000 years of cumulative follow-up. The association between genotype and BCSS was evaluated using Cox proportional hazards regression analysis. Results: In tamoxifen treated patients, there was weak evidence that the poor-metaboliser variant, CYP2D6*6, (MAF=0.01), was associated with decreased BCSS (P=0.02; HR=1.95; 95% CI=1.12-3.40). No other variants, including CYP2D6*4 (MAF=0.20), previously reported to be associated with poorer clinical outcomes, were associated with differences in BCSS, in either the tamoxifen or non-tamoxifen groups. Conclusions: CYP2D6*6 may affect BCSS in tamoxifen-treated patients. However, the absence of an association with survival in more frequent variants, including CYP2D6*4, questions the validity of the reported association between CYP2D6 genotype and treatment response in breast cancer. Until larger, prospective studies confirming any associations are available, routine CYP2D6 genetic testing should not be used in the clinical setting. by Stefania Gastaldi 22 Aug 2010 at 7:00pm Recent findings suggest the involvement of the MET oncogene, encoding the tyrosine kinase receptor for hepatocyte growth factor, in the onset and progression of basal-like breast carcinoma. The expression profiles of basal-like tumors - but not those of other breast cancer subtypes - are enriched for gene sets that are coordinately over-represented in transcriptional signatures regulated by Met. Consistently, tissue microarray analyses have revealed that Met immunoreactivity is much higher in basal-like cases of human breast cancer than in other tumor types. Finally, mouse models expressing mutationally activated forms of Met develop a high incidence of mammary tumors, some of which exhibit basal characteristics. The present review summarizes current knowledge on the role and activity of Met in basal-like breast cancer, with a special emphasis on the correlation between this tumor subtype and the cellular hierarchy of the normal mammary gland. by Marija Plodinec 22 Aug 2010 at 7:00pm Cells constantly encounter physical forces and respond to neighbors and circulating factors by triggering intracellular signaling cascades that in turn affect their behavior. The mechanisms by which cells transduce mechanical signals to downstream biochemical changes are not well understood. In their work, Salaita and coworkers show that the spatial organization of cell surface receptors is crucial for mechanotransduction. Consequently, force modulation that disrupts the mechanochemical coupling may represent a critical step in cancerogenesis. by Jingqin Luo 19 Aug 2010 at 7:00pm Microarray data have been widely utilized to discover biomarkers predictive of response to endocrine therapy in estrogen receptor-positive breast cancer. Typically, these data have focused on analyses conducted on the diagnostic specimen. However, dynamic temporal changes in gene expression associated with treatment may deliver significant improvements to the current generation of predictive models. We present and discuss some statistical issues relevant to the paper by Taylor and colleagues, who conducted studies to model the prognostic potential of gene expression changes that occur after endocrine treatment. |
2 Sep 2010 at 7:00am A study published in the Journal of the American Medical Association suggests that women with a gene mutation linked to breast and ovarian cancer face lower risks of developing such cancer after receiving mastectomies or having their ovaries removed, The Wall Street Journal reports... 2 Sep 2010 at 6:00am Using readily available computer programs, researchers have developed a system to identify genes that will be useful in the classification of breast cancer. The algorithm, described in BioMed Central's open access Journal of Experimental & Clinical Cancer Research will enable researchers to quickly generate valuable gene signatures without specialized software or extensive bioinformatics training... 2 Sep 2010 at 5:00am Specific prevention and education strategies are needed to address breast cancer in Mexican-origin women in this country, according to a study at The University of Texas MD Anderson Cancer Center, which was published online in the journal Cancer... 2 Sep 2010 at 5:00am Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned Roche will continue with its ongoing Phase III EMILIA registration study... 2 Sep 2010 at 3:00am When breast cancer surgeons regularly confer with plastic surgeons prior to surgery, their patients are more likely to have reconstruction, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center. Where a woman goes for breast cancer treatment can vary widely - ranging from small private practices to large hospital settings... 2 Sep 2010 at 3:00am The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate.... 1 Sep 2010 at 8:00am Eisai Inc. announced today that it has received notification from the U.S... 1 Sep 2010 at 7:00am Girls eating a high-fat diet during puberty, even those who do not become overweight or obese, may be at a greater risk of developing breast cancer later in life, according to Michigan State University researchers. The implications - that a high-fat diet may have detrimental effects independent of its effect to cause obesity - could drive new cancer prevention efforts... 1 Sep 2010 at 5:00am A 51-year-old breast cancer patient from Switzerland has become the first person in the world to be treated using Gated RapidArc®, which makes it possible to monitor patient breathing and compensate for tumor motion while quickly delivering radiotherapy during a continuous rotation around the patient... 1 Sep 2010 at 3:00am Women with the inherited mutations of the BRCA1 or BRCA2 genes who had preventive (prophylactic) breast removal (mastectomy) or the removal of the fallopian tubes and ovaries (salpingo-oophorectomy) were found to have a significantly lower risk of developing ovarian and breast cancers, says a study published in JAMA (Journal of the American Medical Association), September 1st issue... 31 Aug 2010 at 6:00am ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops antibody-based targeted anticancer products, announced that Genentech, a member of the Roche Group, announced its receipt of a Refuse to File (RTF) letter from the US Food and Drug Administration (FDA) for the accelerated approval of the Biologic License Application (BLA) for trastuzumab-DM1, or T-DM1, submitted in July 2010... 31 Aug 2010 at 5:00am For the first time, researchers at Fred Hutchinson Cancer Research Center have identified and isolated adult mammary stem cells in mice. Long-term implications of this research may include the use of such cells to regenerate breast tissue, provide a better understanding of the role of adult stem cells in breast cancer development, and develop potential new targets for anti-cancer drugs... 30 Aug 2010 at 4:00am AARP Bulletin: "Two years after undergoing a double mastectomy and chemotherapy so severe she was hospitalized in intensive care for several weeks, breast cancer survivor Denise Hicks should be following what her doctors call 'the plan,'" which includes additional medications and treatments. But she can't. "Hicks has health insurance but already reached her coverage limits... 29 Aug 2010 at 2:00am Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1 (T-DM1) Biologics License Application (BLA). As planned, Genentech will continue with its ongoing Phase III registrational T-DM1 trial, EMILIA... 28 Aug 2010 at 10:00am A new test has been developed which can predict whether a breast cancer patient will respond to chemotherapy within 24-hours of starting treatment, thus sparing her unnecessary treatment and side effects, according to a study published in the medical journal Clinical Cancer Research... |
|
All information in this site is deemed reliable but not guaranteed. Garypedia.com web site owner shall
not be responsible for any typographical errors, misinformation, and misprints and shall be held totally harmless individually.Garypedia.com is an independent provider of links to news articles. Garypedia.com contains links to sites on the internet which are owned and operated by the "External Sites". Garypedia.com is not responsible for the availability of any External Sites. Contact the site administrator or Webmaster for those External Sites if you have any concerns regarding such links or the links located on such External Sites. Garypedia.com is entirely committed to protecting the privacy of its mediapartners and their users. We use a browser feature known as a cookie. One way our cookies are useful is that they help to improve and personalize your experience by increasing a page's responsiveness and decreasing time between downloading as you browse or surf through the site. Additionally, a pixel tag is delivered with the newsfeeds themselves to organize information about online activity as a means to create anonymous profiles that reflect content preferences. No personally identifiable information is stored or collected. Any suggestions, please email us.
Copyright � 2007 Garypedia.com. All rights reserved. |
breast cancer